[Hospital-acquired pneumonia - new guidelines]

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Clinical Microbiology

Background:

• The incidence of multidrug-resistant (MDR) pathogens in nosocomial infections is rising.
• However, national data from Germany indicate no significant shifts in pathogen types for hospital-acquired pneumonia (HAP).
• Individual risk factor assessment for MDR pathogens is crucial for guiding empiric antimicrobial therapy selection.

Purpose of the Study:

• To outline current recommendations for diagnosing and treating hospital-acquired pneumonia (HAP), with a focus on multidrug-resistant (MDR) pathogens.
• To emphasize the importance of risk stratification in selecting appropriate antimicrobial strategies.
• To provide guidance on diagnostic tools and therapeutic approaches for HAP.

Main Methods:

• Review of diagnostic modalities including thoracic ultrasound, procalcitonin, lactate testing, and PCR for influenza.
• Analysis of treatment strategies, including empiric combination therapy, deescalation, and antibiotic dosing based on pharmacokinetic/pharmacodynamic (Pk/Pd) criteria.
• Consideration of adjunctive aerosolized therapy in specific patient populations.

Main Results:

• Thoracic ultrasound, procalcitonin, lactate, and PCR are recommended diagnostic tools.
• Empiric combination therapy is advised only for severe HAP with high MDR risk.
• Deescalation and optimized antibiotic dosing (betalactams) are strongly recommended.

Conclusions:

• Risk factor assessment is central to managing HAP due to MDR pathogens.
• Diagnostic workup should incorporate advanced methods like ultrasound and specific biomarkers.
• Therapeutic strategies should prioritize deescalation and individualized dosing, reserving combination therapy for high-risk severe cases.